Brewing Post-MI Success with Beta-Blockers скачать в хорошем качестве

Brewing Post-MI Success with Beta-Blockers

Presented on April 16, 2025 by Luis Donaldo Delgado, PharmD and Steven Duong, PharmD Over the last few years, there has been new evidence that supports interrupting beta-blocker therapy after one year in patients diagnosed with a myocardial infarction. Although current guidelines support therapy interruption, guidance was based on less robust data. Studies discussed within the presentation may help provide new insight and clinical considerations that may help influence therapeutic decisions in a select patient population. After this presentation, attendees will be able to: 1. Describe the physiological rationale for betablocker therapy following myocardial infarction. 2. Review current guideline recommendations and their supporting evidence for beta-blocker use in managing acute and chronic coronary syndromes. 3. Evaluate recent primary literature regarding the appropriate duration of post-myocardial infarction beta-blocker therapy. 4. Formulate an appropriate treatment regimen for managing beta-blocker therapy post-myocardial infarction based on available evidence and patient-centered considerations.